Please visit our MS learning channel on Youtube, which provides hundreds of topics from our education programs, that were video-recorded and archived here: www.youtube.com/msviewsandnews -- Be empowered with MS news by registering with us: www.register.msviewsandnews.org

joomla ecommerce template -- Scroll left side of this blog for needed resources. Also, use our 'search by topic' tool, to find specific information.

Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.

============================================================

Friday, November 20, 2015

Novel Protein Suppresses MS in Mouse Model, Inhibits Neuroinflammation in Spinal Cord


IL-32 might be a potential new therapeutic avenue for MS
Nov 18, 2015

<span class="entry-title">Novel Protein Suppresses MS in Mouse Model, Inhibits Neuroinflammation in Spinal Cord</span><span class="entry-subtitle">IL-32 might be a potential new therapeutic avenue for MS</span>  November 18, 2015
 In a recent study entitled “Myelin oligodendrocyte glycoprotein (MOG35-55)-induced experimental autoimmune encephalomyelitis is ameliorated in interleukin-32 alpha transgenic mice,” a team of researchers investigated whether interleukin (IL)-32, a cytokine with an established role in rheumatoid arthritis, has a protective function in a mouse model of human multiple sclerosis (MS). The study was published in the journal Oncotarget.
MS is a neurological autoimmune disease characterized by immune destruction of themyelin layer within nerve cells, leading to a wide range of neurological symptoms (affecting sensory, motor, autonomic, and neurocognitive functions) that usually manifests between the ages of 20 and 40 years old. Currently, MS affects approximately 350,000 individuals in the United States.
IL-32 is a novel cytokine (cytokines are small proteins with key functions in cell signaling) expressed in a variety of human organs1 — including the spleen, thymus, leukocyte, lung, small intestine, colon, prostate, heart, placenta, liver, muscle, kidney, pancreas, and brain. IL-32 expression is increased in rheumatoid arthritis, a chronic inflammatory disorder, where its levels correlate with clinical and histological markers of the disease. The role of IL-32, however, on central nervous system injuries and demyelination is currently poorly understood.
In this new study, a team of researchers investigated how IL-32α may affect MS pathogenesis. To this end, they induced in vivo experimental autoimmune encephalomyelitis (EAE), an experimental and widely accepted mouse model of MS, by injecting mice with encephalitogenic peptide, MOG35-55. The same strategy was used in a transgenic mouse that overexpressed the human IL-32α protein (IL-32α transgenic mice).
Continue Reading



~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
MS Views and News helps to provide information for all affected by MS
Keep up to date with the news and information we provide 
by signing up by clicking here
.===================================

No comments: